<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/23454317-ADC4-4369-A212-BF0802191E59"><gtr:id>23454317-ADC4-4369-A212-BF0802191E59</gtr:id><gtr:name>Domainex</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Sch of Chemistry</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/23454317-ADC4-4369-A212-BF0802191E59"><gtr:id>23454317-ADC4-4369-A212-BF0802191E59</gtr:id><gtr:name>Domainex</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/895981F0-AD63-4E61-8D6A-FB5672D9D2E6"><gtr:id>895981F0-AD63-4E61-8D6A-FB5672D9D2E6</gtr:id><gtr:firstName>Jacquie</gtr:firstName><gtr:surname>Bond</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D5EFBF0C-D6EC-48B1-B5C8-D211482E7B44"><gtr:id>D5EFBF0C-D6EC-48B1-B5C8-D211482E7B44</gtr:id><gtr:firstName>Adam</gtr:firstName><gtr:otherNames>Stephen</gtr:otherNames><gtr:surname>Nelson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/96938CDE-C7C1-4E1A-B3A5-16A17ECCD713"><gtr:id>96938CDE-C7C1-4E1A-B3A5-16A17ECCD713</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:otherNames>Laurence</gtr:otherNames><gtr:surname>Warriner</gtr:surname><gtr:orcidId>0000-0002-7589-6011</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/995A6779-A931-4123-825F-12980C01DCD2"><gtr:id>995A6779-A931-4123-825F-12980C01DCD2</gtr:id><gtr:firstName>Ewan</gtr:firstName><gtr:otherNames>Evander</gtr:otherNames><gtr:surname>Morrison</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FF043503%2F1"><gtr:id>49A6994F-3A6D-4AF8-8EF2-35654813CE8B</gtr:id><gtr:title>Probing the extraordinary bioactivity of macrocyclic natural products: privileged motifs or biosynthetic artefacts?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/F043503/1</gtr:grantReference><gtr:abstractText>The fields of Chemical Biology and Medicinal Chemistry require collections of molecules which are likely to be biogically active. Such collections can be screened to identify small molecules which interact with biological molecules such as proteins. Such small molecules can reveal fundamental insights into biological processes and can sometimes be ultimately used to treat diseases.The grant will explore the fundamental principles which chemists can use to design collections of small molecules. Naturally occurring small molecules, known as natural products, are necessarily biologically active. Many of these molecules have large cyclic structures. This grant will explore whether this type of structure predisposes small molecules towards biological activity.A collection of natural product-like small molecules will be prepared by extending diversity-oriented chemistry which has been developed through Professor Nelson's EPSRC Advanced fellowship. Some of these molecules will have large cyclic structures, and others will not. The molecules will be screened for a broad range of biological activities. By comparing the biological profiles of the classes of molecules, we will be able to address the fundamental chemical question of whether macrocyclic molecules are fundamentally predisposed towards biological activity. In addition, the grant will encourage postdoctoral mobility between physical and life sciences, and sufficient priority for EPSRC issued to issue a recent call.</gtr:abstractText><gtr:fund><gtr:end>2012-12-10</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2008-11-07</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>420890</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PPIs</gtr:description><gtr:id>D25A38AC-EB6B-4AD6-8C59-8A46100D40B7</gtr:id><gtr:impact>N/A- only just started</gtr:impact><gtr:outcomeId>56b0e024256a09.85996593-1</gtr:outcomeId><gtr:partnerContribution>Expertise, assays, other assets, collaboration, secondments</gtr:partnerContribution><gtr:piContribution>Leeds is leading an EPSRC programme grant on protein-protein interactions that involves AstraZeneca, Domainex and Northern Institute for Cancer Research</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PPIs</gtr:description><gtr:id>2913A638-F9F4-49C6-B243-4AA2E9BB269B</gtr:id><gtr:impact>N/A- only just started</gtr:impact><gtr:outcomeId>56b0e024256a09.85996593-3</gtr:outcomeId><gtr:partnerContribution>Expertise, assays, other assets, collaboration, secondments</gtr:partnerContribution><gtr:piContribution>Leeds is leading an EPSRC programme grant on protein-protein interactions that involves AstraZeneca, Domainex and Northern Institute for Cancer Research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Domainex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PPIs</gtr:description><gtr:id>0F390303-6866-487D-BAE3-1F3AFD4607E7</gtr:id><gtr:impact>N/A- only just started</gtr:impact><gtr:outcomeId>56b0e024256a09.85996593-2</gtr:outcomeId><gtr:partnerContribution>Expertise, assays, other assets, collaboration, secondments</gtr:partnerContribution><gtr:piContribution>Leeds is leading an EPSRC programme grant on protein-protein interactions that involves AstraZeneca, Domainex and Northern Institute for Cancer Research</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute for Molecular Physiology</gtr:department><gtr:description>MPI</gtr:description><gtr:id>DAA29CDC-438F-4003-843C-1D63B7B6E049</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>545b511215fa94.76061667-1</gtr:outcomeId><gtr:partnerContribution>HT screening and follow-up biology</gtr:partnerContribution><gtr:piContribution>Screening compounds</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>AZ screening</gtr:description><gtr:id>181A6B88-CC88-450A-BB96-726B750D0AF3</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545b4f9bdd44d6.97397290-1</gtr:outcomeId><gtr:partnerContribution>HT screening</gtr:partnerContribution><gtr:piContribution>Screening compounds</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC programme grant</gtr:description><gtr:end>2021-01-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/N013573/1</gtr:fundingRef><gtr:id>F6ABFB73-F58D-4949-9B7F-069DD6675250</gtr:id><gtr:outcomeId>56b0e0c186f0a6.70148885</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>IMI European Lead Factory</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Molecular Biology Organisation</gtr:fundingOrg><gtr:id>19FA8B58-6A4C-4526-B1E9-627AB394A1AB</gtr:id><gtr:outcomeId>545b52e2704ab0.23589184</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Compounds based on the macrocyclic scaffolds have been evaluated for biological function through a pharmaceutical company open innovation scheme</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>0768273C-88B0-4109-8FF7-468A81E98E7E</gtr:id><gtr:impactTypes/><gtr:outcomeId>56c2ed5baa7247.64115407</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Robust methods for the preparation of natural product-like macrocycles have been developed (an under-represented structural class in screening collections).</gtr:description><gtr:exploitationPathways>Compounds based on the scaffolds have been screened by both pharmaceutical companies and academic chemical biology units.</gtr:exploitationPathways><gtr:id>9F63F039-A0EE-43BE-B99F-1339B0816513</gtr:id><gtr:outcomeId>56c2edab0f3369.17614745</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0CEB91B9-84DC-4A70-80F3-9C1BAB86F64E</gtr:id><gtr:title>Modular Synthesis of Diverse Natural Product-Like Macrocycles: Discovery of Hits with Antimycobacterial Activity.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/447725cb239c006684f637f5490d3f5a"><gtr:id>447725cb239c006684f637f5490d3f5a</gtr:id><gtr:otherNames>Dow M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn><gtr:outcomeId>5a2febda078831.19264849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1FADF7A-170B-42E4-9147-D05439EDDD1D</gtr:id><gtr:title>Towards the systematic exploration of chemical space.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/447725cb239c006684f637f5490d3f5a"><gtr:id>447725cb239c006684f637f5490d3f5a</gtr:id><gtr:otherNames>Dow M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>545b4384eabf03.81980622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C255D96B-3422-4F32-B4F8-91856F57C072</gtr:id><gtr:title>High-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markers.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32e4906de2b4aa2073dafccdb03f8048"><gtr:id>32e4906de2b4aa2073dafccdb03f8048</gtr:id><gtr:otherNames>Martin HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545b4383d288e5.08185270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AF885B0-CE0C-4F7E-B4F3-D579692665B8</gtr:id><gtr:title>Innovative approaches to the design and synthesis of small molecule libraries.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1bdbde76fbb96c671458c550027fd0e"><gtr:id>d1bdbde76fbb96c671458c550027fd0e</gtr:id><gtr:otherNames>Nelson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>56b0dedc2aa3f6.31206031</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/F043503/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>80</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>80</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>02567418-12CB-462E-9092-530C6E63B359</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Chemical Biology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>